How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 70.4 | 70.4 | 70.5 | 66.8 | 66.8 | 67.6 | -2.9 |
| Healthcare | 26.7 | 26.7 | 27.6 | 27.7 | 27.7 | 27.5 | +0.8 |
| Chemicals | 1.1 | 1.1 | 0.6 | · | · | · | -0.5 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 8.54% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| AJANTPHARM | Pharma | 5.08% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| DIVISLAB | Pharma | 4.74% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| GLAND | Pharma | 4.11% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| CAPLIPOINT | Pharma | 4.02% | 10 | 9 | 2 | 1 | 4 | 0/2 | +50.2% |
| LUPIN | Pharma | 3.77% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| APOLLOHOSP | Healthcare | 3.52% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| ALKEM | Pharma | 3.14% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
| DRREDDY | Pharma | 3.01% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| MAXHEALTH | Healthcare | 2.98% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| FORTIS | Healthcare | 2.93% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| IPCALAB | Pharma | 2.73% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| MEDANTA | Healthcare | 2.61% | 9 | 9 | 6 | 8 | 2 | 0/2 | +23.2% |
| ANTHEM | Pharma | 2.49% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| COHANCE | Healthcare | 2.44% | 4 | 5 | 4 | 10 | 4 | 0/2 | +13.2% |
| GLENMARK | Pharma | 2.18% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| SAILIFE | Healthcare | 2.17% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| RAINBOW | Healthcare | 2.06% | 10 | 7 | 2 | 5 | 4 | 1/2 | +15.3% |
| ASTERDM | Healthcare | 1.95% | 10 | 4 | 8 | 3 | 1 | 1/2 | +15.1% |
| AUROPHARMA | Pharma | 1.93% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| CIPLA | Pharma | 1.68% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| ERIS | Pharma | 1.48% | 5 | 7 | 5 | 6 | 6 | 0/2 | +1.0% |
| VIJAYA | Pharma | 1.37% | 8 | 10 | 4 | 2 | 1 | 0/2 | +37.0% |
| LALPATHLAB | Healthcare | 1.26% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| PFIZER | Healthcare | 1.17% | 3 | 7 | 1 | 2 | 7 | 0/2 | -9.0% |
| EMCURE | Pharma | 0.97% | 8 | 10 | 5 | 5 | 3 | 0/2 | +9.8% |
| KIMS | Healthcare | 0.87% | 7 | 3 | 7 | 4 | 1 | 0/2 | +19.2% |
| JUBLPHARMA | Pharma | 0.67% | 5 | 2 | 3 | 6 | 6 | 0/2 | +5.5% |
| BIOCON | Pharma | 0.64% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| SYNGENE | Healthcare | 0.55% | 2 | 3 | 6 | 9 | 7 | 0/2 | -0.6% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹196 (+96%), vs ₹169 for Nifty 500 (+69%) and ₹152 for Nifty 50 (+52%). Its relative-strength line ended at 129 vs Nifty 50 and 116 vs Nifty 500 — above 100, sustained outperformance.